Skip to content

Effect of Hijamah (wet cupping)in management of cervical spondylosis

A RANDOMIZED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF HIJAMAH-BIL-SHART IN CERVICAL SPONDYLOSIS

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009384
Enrollment
60
Registered
2017-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CERVICAL SPONDYLOSIS

Interventions

Intervention1: HIJAMAH BIL SHART: WET CUPPING WILL BE DONE IN BOTH GROUPS ON DIFFERENT SITES Control Intervention1: SITE OF HIJAMAH: BOTH GROUPS ARE COMPARATIVE TO EACH OTHER WITH RESPECT TO THE SITE

Sponsors

JAMIA HAMDARD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 30 to 65 yrs. Sex: All genders Patients with signs and symptoms of cervical spondylosis(with or without radicular symptoms) AND radiological changes suggestive of the disease Patients, who will be willing to discontinue all NSAIDs or other analgesic medication taken for any condition Willing to sign the informed consent, follow the protocol and participate in clinical trial voluntarily

Exclusion criteria

Exclusion criteria: Below 30 and above 65 yrs. Other Diseases of cervical spine like Ankylosing spondylitis, arthritis of neck (except osteoarthritis),Vascular lesions and Neoplasms Trauma of neck, wry neck (Torticollis), Cervical rib syndrome Local wound and infection over neck Spinal cord disorders Carpal tunnel syndrome Anemia (Hb Preg¬nancy and lactation(6 months post-delivery) Bleeding Disorders, Patients on anticoagulant treatment / disseminated intravascular coagulation Patients with systemic disorders like chronic liver, kidney or heart disease Patients of uncontrolled diabetes mellitus Terminally ill patients Patients taking any other type of medicinal (NSAIDs, corticosteroid etc) and non-medicinal treatment for cervical spondylosis Unwilling patients

Design outcomes

Primary

MeasureTime frame
VAS NDI SF12 CROM SIGN AND SYMPTOMSTimepoint: 0 day, 14th day, 21st day and 42nd day

Secondary

MeasureTime frame
CBCTimepoint: DAY 0, DAY 42

Countries

India

Contacts

Public ContactDR SHAZIA JILANI

JAMIA HAMDARD

ajabin@jamiahamdard.ac.in9899315252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026